- Home
- PAVM vs PPBT Comparison
PAVM vs PPBT Comparison
Compare PAVM & PPBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAVM
- PPBT
- Stock Information
- Founded
- PAVM 2014
- PPBT 2010
- Country
- PAVM United States
- PPBT Israel
- Employees
- PAVM N/A
- PPBT N/A
- Industry
- PAVM Medical/Dental Instruments
- PPBT Biotechnology: Pharmaceutical Preparations
- Sector
- PAVM Health Care
- PPBT Health Care
- Exchange
- PAVM Nasdaq
- PPBT Nasdaq
- Market Cap
- PAVM 12.0M
- PPBT 6.3M
- IPO Year
- PAVM 2016
- PPBT N/A
- Fundamental
- Price
- PAVM $0.60
- PPBT $2.49
- Analyst Decision
- PAVM Strong Buy
- PPBT Strong Buy
- Analyst Count
- PAVM 1
- PPBT 1
- Target Price
- PAVM $19.00
- PPBT $33.00
- AVG Volume (30 Days)
- PAVM 149.7K
- PPBT 22.4K
- Earning Date
- PAVM 08-11-2025
- PPBT 08-15-2025
- Dividend Yield
- PAVM N/A
- PPBT N/A
- EPS Growth
- PAVM N/A
- PPBT N/A
- EPS
- PAVM 0.96
- PPBT N/A
- Revenue
- PAVM $1,993,000.00
- PPBT N/A
- Revenue This Year
- PAVM N/A
- PPBT N/A
- Revenue Next Year
- PAVM $455.63
- PPBT N/A
- P/E Ratio
- PAVM $0.62
- PPBT N/A
- Revenue Growth
- PAVM N/A
- PPBT N/A
- 52 Week Low
- PAVM $0.55
- PPBT $2.00
- 52 Week High
- PAVM $1.90
- PPBT $13.95
- Technical
- Relative Strength Index (RSI)
- PAVM 42.72
- PPBT 52.01
- Support Level
- PAVM $0.57
- PPBT $2.26
- Resistance Level
- PAVM $0.62
- PPBT $2.50
- Average True Range (ATR)
- PAVM 0.04
- PPBT 0.13
- MACD
- PAVM -0.00
- PPBT 0.00
- Stochastic Oscillator
- PAVM 23.46
- PPBT 58.82
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.